Does the media refer more to RCEL or PRCT?

In the previous week, PROCEPT BioRobotics had 34 more articles in the media than Avita Medical. MarketBeat recorded 35 mentions for PROCEPT BioRobotics and 1 mentions for Avita Medical. Avita Medical's average media sentiment score of 0.99 beat PROCEPT BioRobotics' score of 0.24 indicating that Avita Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avita Medical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PROCEPT BioRobotics 6 Very Positive mention(s) 3 Positive mention(s) 26 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RCEL or STAA?

In the previous week, STAAR Surgical had 5 more articles in the media than Avita Medical. MarketBeat recorded 6 mentions for STAAR Surgical and 1 mentions for Avita Medical. Avita Medical's average media sentiment score of 0.99 beat STAAR Surgical's score of -0.07 indicating that Avita Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avita Medical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive STAAR Surgical 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, RCEL or BVS?

Bioventus has higher revenue and earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avita Medical $71.61M 4.37 -$48.59M -$1.44 N/A Bioventus $568.09M 2.02 $22.73M $0.77 17.70

Does the media refer more to RCEL or BVS?

In the previous week, Bioventus had 1 more articles in the media than Avita Medical. MarketBeat recorded 2 mentions for Bioventus and 1 mentions for Avita Medical. Avita Medical's average media sentiment score of 0.99 beat Bioventus' score of 0.51 indicating that Avita Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avita Medical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, IRMD or RCEL?

iRadimed has higher revenue and earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRadimed $83.81M 12.75 $22.48M $1.79 46.68 Avita Medical $71.61M 4.37 -$48.59M -$1.44 N/A

Is IRMD or RCEL more profitable?

iRadimed has a net margin of 26.70% compared to Avita Medical's net margin of -56.96%. iRadimed's return on equity of 23.45% beat Avita Medical's return on equity. Company Net Margins Return on Equity Return on Assets iRadimed 26.70% 23.45% 20.36% Avita Medical -56.96% N/A -78.53%

Does the media prefer IRMD or RCEL?

In the previous week, iRadimed had 6 more articles in the media than Avita Medical. MarketBeat recorded 7 mentions for iRadimed and 1 mentions for Avita Medical. Avita Medical's average media sentiment score of 0.99 beat iRadimed's score of 0.98 indicating that Avita Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avita Medical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RCEL or NNNN?

Avita Medical currently has a consensus target price of $11.40, indicating a potential upside of 12.20%. Given Avita Medical's stronger consensus rating and higher possible upside, analysts plainly believe Avita Medical is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avita Medical 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, RCEL or NNNN?

Anbio Biotechnology has lower revenue, but higher earnings than Avita Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avita Medical $71.61M 4.37 -$48.59M -$1.44 N/A Anbio Biotechnology $8.65M 107.63 $6.40M N/A N/A

Is RCEL or NNNN more profitable?

Anbio Biotechnology has a net margin of 0.00% compared to Avita Medical's net margin of -56.96%. Company Net Margins Return on Equity Return on Assets Avita Medical -56.96% N/A -78.53% Anbio Biotechnology N/A N/A N/A

Avita Medical (RCEL) Competitors

$10.16 -0.25 (-2.40%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$10.48 +0.32 (+3.18%)

As of 09/9/2026 07:59 PM Eastern

Compare

RCEL vs. PRCT, STAA, BVS, IRMD, and NNNN

Should you buy Avita Medical stock or one of its competitors? Avita Medical's main competitors and comparable companies include PROCEPT BioRobotics (PRCT), STAAR Surgical (STAA), Bioventus (BVS), iRadimed (IRMD), and Anbio Biotechnology (NNNN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Avita Medical compare to PROCEPT BioRobotics?

Avita Medical (NASDAQ:RCEL) and PROCEPT BioRobotics (NASDAQ:PRCT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Avita Medical has higher earnings, but lower revenue than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Avita Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avita Medical	$71.61M	4.37	-$48.59M	-$1.44	N/A
PROCEPT BioRobotics	$308.05M	3.86	-$95.57M	-$1.94	N/A

In the previous week, PROCEPT BioRobotics had 34 more articles in the media than Avita Medical. MarketBeat recorded 35 mentions for PROCEPT BioRobotics and 1 mentions for Avita Medical. Avita Medical's average media sentiment score of 0.99 beat PROCEPT BioRobotics' score of 0.24 indicating that Avita Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avita Medical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PROCEPT BioRobotics	6 Very Positive mention(s)	3 Positive mention(s)	26 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PROCEPT BioRobotics has a net margin of -32.53% compared to Avita Medical's net margin of -56.96%. Avita Medical's return on equity of 0.00% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avita Medical	-56.96%	N/A	-78.53%
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%

Avita Medical has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

Avita Medical presently has a consensus price target of $11.40, indicating a potential upside of 12.20%. PROCEPT BioRobotics has a consensus price target of $25.09, indicating a potential upside of 20.98%. Given PROCEPT BioRobotics' higher probable upside, analysts clearly believe PROCEPT BioRobotics is more favorable than Avita Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avita Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
PROCEPT BioRobotics	2 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.19

27.7% of Avita Medical shares are held by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are held by institutional investors. 2.2% of Avita Medical shares are held by company insiders. Comparatively, 4.0% of PROCEPT BioRobotics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Avita Medical beats PROCEPT BioRobotics on 9 of the 17 factors compared between the two stocks.

How does Avita Medical compare to STAAR Surgical?

Avita Medical (NASDAQ:RCEL) and STAAR Surgical (NASDAQ:STAA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

27.7% of Avita Medical shares are held by institutional investors. Comparatively, 96.7% of STAAR Surgical shares are held by institutional investors. 2.2% of Avita Medical shares are held by insiders. Comparatively, 39.9% of STAAR Surgical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Avita Medical has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market. Comparatively, STAAR Surgical has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

Avita Medical currently has a consensus price target of $11.40, indicating a potential upside of 12.20%. STAAR Surgical has a consensus price target of $28.40, indicating a potential upside of 20.24%. Given STAAR Surgical's higher probable upside, analysts plainly believe STAAR Surgical is more favorable than Avita Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avita Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
STAAR Surgical	3 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

In the previous week, STAAR Surgical had 5 more articles in the media than Avita Medical. MarketBeat recorded 6 mentions for STAAR Surgical and 1 mentions for Avita Medical. Avita Medical's average media sentiment score of 0.99 beat STAAR Surgical's score of -0.07 indicating that Avita Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avita Medical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
STAAR Surgical	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

STAAR Surgical has a net margin of 1.13% compared to Avita Medical's net margin of -56.96%. STAAR Surgical's return on equity of 9.05% beat Avita Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avita Medical	-56.96%	N/A	-78.53%
STAAR Surgical	1.13%	9.05%	6.99%

Avita Medical has higher earnings, but lower revenue than STAAR Surgical. Avita Medical is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avita Medical	$71.61M	4.37	-$48.59M	-$1.44	N/A
STAAR Surgical	$239.44M	4.95	-$80.45M	$0.07	337.43

Summary

STAAR Surgical beats Avita Medical on 11 of the 16 factors compared between the two stocks.

How does Avita Medical compare to Bioventus?

Avita Medical (NASDAQ:RCEL) and Bioventus (NASDAQ:BVS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Avita Medical has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market. Comparatively, Bioventus has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

27.7% of Avita Medical shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 2.2% of Avita Medical shares are held by company insiders. Comparatively, 33.5% of Bioventus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Bioventus has higher revenue and earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avita Medical	$71.61M	4.37	-$48.59M	-$1.44	N/A
Bioventus	$568.09M	2.02	$22.73M	$0.77	17.70

In the previous week, Bioventus had 1 more articles in the media than Avita Medical. MarketBeat recorded 2 mentions for Bioventus and 1 mentions for Avita Medical. Avita Medical's average media sentiment score of 0.99 beat Bioventus' score of 0.51 indicating that Avita Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avita Medical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avita Medical presently has a consensus target price of $11.40, suggesting a potential upside of 12.20%. Bioventus has a consensus target price of $16.80, suggesting a potential upside of 23.26%. Given Bioventus' stronger consensus rating and higher probable upside, analysts clearly believe Bioventus is more favorable than Avita Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avita Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Bioventus	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Bioventus has a net margin of 9.36% compared to Avita Medical's net margin of -56.96%. Bioventus' return on equity of 28.08% beat Avita Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avita Medical	-56.96%	N/A	-78.53%
Bioventus	9.36%	28.08%	9.82%

Summary

Bioventus beats Avita Medical on 12 of the 15 factors compared between the two stocks.

How does Avita Medical compare to iRadimed?

iRadimed (NASDAQ:IRMD) and Avita Medical (NASDAQ:RCEL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

92.3% of iRadimed shares are held by institutional investors. Comparatively, 27.7% of Avita Medical shares are held by institutional investors. 34.6% of iRadimed shares are held by company insiders. Comparatively, 2.2% of Avita Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, iRadimed had 6 more articles in the media than Avita Medical. MarketBeat recorded 7 mentions for iRadimed and 1 mentions for Avita Medical. Avita Medical's average media sentiment score of 0.99 beat iRadimed's score of 0.98 indicating that Avita Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avita Medical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iRadimed has a net margin of 26.70% compared to Avita Medical's net margin of -56.96%. iRadimed's return on equity of 23.45% beat Avita Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.45%	20.36%
Avita Medical	-56.96%	N/A	-78.53%

iRadimed has higher revenue and earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	12.75	$22.48M	$1.79	46.68
Avita Medical	$71.61M	4.37	-$48.59M	-$1.44	N/A

iRadimed has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Avita Medical has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market.

iRadimed presently has a consensus target price of $120.00, suggesting a potential upside of 43.61%. Avita Medical has a consensus target price of $11.40, suggesting a potential upside of 12.20%. Given iRadimed's stronger consensus rating and higher probable upside, analysts plainly believe iRadimed is more favorable than Avita Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.80
Avita Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

iRadimed beats Avita Medical on 14 of the 17 factors compared between the two stocks.

How does Avita Medical compare to Anbio Biotechnology?

Avita Medical (NASDAQ:RCEL) and Anbio Biotechnology (NASDAQ:NNNN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

27.7% of Avita Medical shares are owned by institutional investors. 2.2% of Avita Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Avita Medical currently has a consensus target price of $11.40, indicating a potential upside of 12.20%. Given Avita Medical's stronger consensus rating and higher possible upside, analysts plainly believe Avita Medical is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avita Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Anbio Biotechnology has lower revenue, but higher earnings than Avita Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avita Medical	$71.61M	4.37	-$48.59M	-$1.44	N/A
Anbio Biotechnology	$8.65M	107.63	$6.40M	N/A	N/A

In the previous week, Avita Medical had 1 more articles in the media than Anbio Biotechnology. MarketBeat recorded 1 mentions for Avita Medical and 0 mentions for Anbio Biotechnology. Avita Medical's average media sentiment score of 0.99 beat Anbio Biotechnology's score of 0.00 indicating that Avita Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Avita Medical	Positive
Anbio Biotechnology	Neutral

Anbio Biotechnology has a net margin of 0.00% compared to Avita Medical's net margin of -56.96%.

Company	Net Margins	Return on Equity	Return on Assets
Avita Medical	-56.96%	N/A	-78.53%
Anbio Biotechnology	N/A	N/A	N/A

Avita Medical has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.17, indicating that its share price is 417% more volatile than the broader market.

Summary

Avita Medical beats Anbio Biotechnology on 8 of the 13 factors compared between the two stocks.

Get Avita Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCEL vs. The Competition

Export

Metric	Avita Medical	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$320.39M	$5.57B	$7.22B	$12.88B
Dividend Yield	N/A	1.78%	2.55%	9.95%
P/E Ratio	-7.06	24.83	271.79	25.29
Price / Sales	4.37	71.76	709.75	113.08
Price / Cash	N/A	32.78	77.55	52.32
Price / Book	-18.47	6.00	10.63	6.26
Net Income	-$48.59M	$150.94M	$3.48B	$357.86M
7 Day Performance	-7.13%	-1.91%	-1.19%	-0.56%
1 Month Performance	33.68%	-2.05%	1.99%	-1.04%
1 Year Performance	143.65%	9.12%	21.89%	11.31%

Avita Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCEL Avita Medical	2.8855 of 5 stars	$10.16 -2.4%	$11.40 +12.2%	+142.5%	$320.39M	$71.61M	N/A	130
PRCT PROCEPT BioRobotics	3.307 of 5 stars	$20.48 -3.4%	$28.00 +36.7%	-47.5%	$1.17B	$308.05M	N/A	430	Trending News Analyst Forecast
STAA STAAR Surgical	3.2564 of 5 stars	$23.02 +1.9%	$28.40 +23.4%	-14.7%	$1.15B	$239.44M	328.70	1,211
BVS Bioventus	4.5202 of 5 stars	$13.55 -0.7%	$16.80 +24.0%	+87.5%	$1.14B	$581.85M	17.61	1,200
IRMD iRadimed	2.7934 of 5 stars	$87.42 +1.2%	$120.00 +37.3%	+16.2%	$1.12B	$83.81M	48.83	110	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RCEL) was last updated on 9/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avita Medical (RCEL) Competitors

RCEL vs. PRCT, STAA, BVS, IRMD, and NNNN

How does Avita Medical compare to PROCEPT BioRobotics?

Summary

How does Avita Medical compare to STAAR Surgical?

Summary

How does Avita Medical compare to Bioventus?

Summary

How does Avita Medical compare to iRadimed?

Summary

How does Avita Medical compare to Anbio Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCEL vs. The Competition

Avita Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avita Medical (RCEL) Competitors

RCEL vs. PRCT, STAA, BVS, IRMD, and NNNN

How does Avita Medical compare to PROCEPT BioRobotics?

Which has preferable valuation and earnings, RCEL or PRCT?

Does the media refer more to RCEL or PRCT?

Is RCEL or PRCT more profitable?

Which has more risk and volatility, RCEL or PRCT?

Do analysts rate RCEL or PRCT?

Do institutionals & insiders believe in RCEL or PRCT?

Summary

How does Avita Medical compare to STAAR Surgical?

Do insiders and institutionals have more ownership in RCEL or STAA?

Which has more risk & volatility, RCEL or STAA?

Do analysts recommend RCEL or STAA?

Does the media favor RCEL or STAA?

Is RCEL or STAA more profitable?

Which has preferable earnings and valuation, RCEL or STAA?

Summary

How does Avita Medical compare to Bioventus?

Which has more risk & volatility, RCEL or BVS?

Do insiders & institutionals believe in RCEL or BVS?

Which has better earnings & valuation, RCEL or BVS?

Does the media refer more to RCEL or BVS?

Do analysts prefer RCEL or BVS?

Is RCEL or BVS more profitable?

Summary

How does Avita Medical compare to iRadimed?

Do insiders and institutionals hold more shares of IRMD or RCEL?

Does the media prefer IRMD or RCEL?

Is IRMD or RCEL more profitable?

Which has stronger earnings and valuation, IRMD or RCEL?

Which has more risk & volatility, IRMD or RCEL?

Do analysts recommend IRMD or RCEL?

Summary

How does Avita Medical compare to Anbio Biotechnology?

Do insiders and institutionals have more ownership in RCEL or NNNN?

Do analysts prefer RCEL or NNNN?

Which has stronger valuation and earnings, RCEL or NNNN?

Does the media refer more to RCEL or NNNN?

Is RCEL or NNNN more profitable?

Which has more volatility and risk, RCEL or NNNN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCEL vs. The Competition

Avita Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools